Imatinib mesylate
Orphan DrugFDA Approved, EMA Approved
Contents
Description
Imatinib is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR. It is used in the treatment of various hematologic malignancies and has shown efficacy in systemic mastocytosis including urticaria pigmentosa. The drug works by blocking abnormal protein signaling in affected cells.
Indications & Therapeutic Use
chronic myeloid leukemia, acute lymphoblastic leukemia, systemic mastocytosis, urticaria pigmentosa, gastrointestinal stromal tumors
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Imatinib mesylate — GNH India
14 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Gleevec
100 mg/1tabletUSA
Glivec 100mg
100mgtabletSwitzerland
Imatinib Mesylate
100 mg/1tablet, film coatedUSA
Glivec 400mg
400mgtabletSwitzerland
IMAGET 400mg
400mgtabletIndia
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Imatinib mesylate
| Generic Name | imatinib mesylate |
| Brands | 1 brand available |
| Active Ingredient | imatinib mesylate |
| Drug Class | chronic myeloid leukemia |
| Manufacturer | Novartis |
| Dosage Forms | Oral tablet, 100mg, 400mg |
| Medical Code | L01EA01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00001459 |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes